Literature DB >> 7544928

PPBP [4-phenyl-1-(4-phenylbutyl) piperidine], a potent sigma-receptor ligand, decreases brain injury after transient focal ischemia in cats.

H Takahashi1, J R Kirsch, K Hashimoto, E D London, R C Koehler, R J Traystman.   

Abstract

BACKGROUND AND
PURPOSE: We tested the hypothesis that administration of 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP), a potent sigma-receptor ligand, during transient focal ischemia would affect early postischemic brain injury.
METHODS: Halothane-anesthetized cats underwent left middle cerebral artery occlusion for 90 minutes followed by 4 hours of reperfusion. Control cats received saline (n = 10). Experimental cats (2 groups, n = 10 per group) were treated with PPBP at a rate of 0.1 mumol/kg per hour (PPBP-0.1) or administered 1 mumol/kg per hour (PPBP-1) intravenously from 75 minutes after initiation of ischemia and continuing during the 4 hours of reperfusion.
RESULTS: As measured by the microsphere method, blood flow to the ipsilateral caudate nucleus was decreased similarly in all groups during ischemia. Blood flow to the ipsilateral inferior temporal cortex was decreased during ischemia in all groups but was higher in cats subsequently treated with PPBP at the highest dose, even before drug administration. There was no difference in blood flow to the ipsilateral caudate nucleus or inferior temporal cortex (area of greatest cortical injury) during reperfusion. Triphenyltetrazolium-determined injury volume of the ipsilateral cerebral hemisphere (control, 29 +/- 5%; PPBP-0.1, 17 +/- 3%; PPBP-1, 6 +/- 1% of ipsilateral hemisphere; mean +/- SEM) and caudate nucleus (control, 49 +/- 5%; PPBP-0.1, 39 +/- 6%; PPBP-1, 25 +/- 5% of ipsilateral caudate nucleus) was less in cats treated with 1 mumol/kg per hour of PPBP compared with cats treated with saline. Cats treated with 0.1 mumol/kg per hour had a 45% smaller hemispheric injury volume than the control group without differences in intraischemic blood flow. Recovery of somatosensory evoked potential amplitude was greater in cats treated with PPBP-1 compared with control (control, 18 +/- 11%; PPBP-0.1, 30 +/- 14%; PPBP-1, 54 +/- 14% of baseline).
CONCLUSIONS: These data indicate that sigma-receptors may play an important role in the mechanism of acute injury in both the cortex and the caudate nucleus after 90 minutes of transient focal ischemia in the cat. Because PPBP afforded protection when administered at the end of ischemia and during reperfusion, sigma-receptors may contribute to the progression of injury in ischemic border regions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7544928     DOI: 10.1161/01.str.26.9.1676

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  8 in total

Review 1.  Sigma-1 Receptors and Neurodegenerative Diseases: Towards a Hypothesis of Sigma-1 Receptors as Amplifiers of Neurodegeneration and Neuroprotection.

Authors:  Linda Nguyen; Brandon P Lucke-Wold; Shona Mookerjee; Nidhi Kaushal; Rae R Matsumoto
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

2.  Sigma receptor ligand 4-phenyl-1-(4-phenylbutyl)-piperidine modulates neuronal nitric oxide synthase/postsynaptic density-95 coupling mechanisms and protects against neonatal ischemic degeneration of striatal neurons.

Authors:  Zeng-Jin Yang; Erin L Carter; Michel T Torbey; Lee J Martin; Raymond C Koehler
Journal:  Exp Neurol       Date:  2009-10-31       Impact factor: 5.330

3.  Administration of a Sigma Receptor Agonist Delays MCAO-Induced Neurodegeneration and White Matter Injury.

Authors:  Christopher C Leonardo; Aaron A Hall; Lisa A Collier; Suzanne M Green; Alison E Willing; Keith R Pennypacker
Journal:  Transl Stroke Res       Date:  2010-06       Impact factor: 6.829

Review 4.  Perinatal hypoxic-ischemic brain injury in large animal models: Relevance to human neonatal encephalopathy.

Authors:  Raymond C Koehler; Zeng-Jin Yang; Jennifer K Lee; Lee J Martin
Journal:  J Cereb Blood Flow Metab       Date:  2018-08-28       Impact factor: 6.200

5.  Sigma receptor agonists provide neuroprotection in vitro by preserving bcl-2.

Authors:  Sufang Yang; Anish Bhardwaj; Jian Cheng; Nabil J Alkayed; Patricia D Hurn; Jeffrey R Kirsch
Journal:  Anesth Analg       Date:  2007-05       Impact factor: 5.108

6.  A prototypical Sigma-1 receptor antagonist protects against brain ischemia.

Authors:  John A Schetz; Evelyn Perez; Ran Liu; Shiuhwei Chen; Ivan Lee; James W Simpkins
Journal:  Brain Res       Date:  2007-09-12       Impact factor: 3.252

7.  Cyclic adenosine monophosphate response element-binding protein phosphorylation and neuroprotection by 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP).

Authors:  Sufang Yang; Nabil J Alkayed; Patricia D Hurn; Jeffrey R Kirsch
Journal:  Anesth Analg       Date:  2009-03       Impact factor: 5.108

8.  Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways.

Authors:  Tomoko Nishimura; Tamaki Ishima; Masaomi Iyo; Kenji Hashimoto
Journal:  PLoS One       Date:  2008-07-02       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.